Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Outstanding (Weighted Average): 2015-2024

Historic Shares Outstanding (Weighted Average) for Aclaris Therapeutics (ACRS) over the last 10 years, with Dec 2024 value amounting to $71.4 million.

  • Aclaris Therapeutics' Shares Outstanding (Weighted Average) rose 51.84% to $108.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.3 million, marking a year-over-year increase of 51.84%. This contributed to the annual value of $71.4 million for FY2024, which is 0.84% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $71.4 million for FY2024, which was up 0.84% from $70.8 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $71.4 million in FY2024 and a low of $42.9 million during FY2020.
  • In the last 3 years, Aclaris Therapeutics' Shares Outstanding (Weighted Average) had a median value of $70.8 million in 2023 and averaged $69.7 million.
  • Data for Aclaris Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 42.66% (in 2021) over the last 5 years.
  • Aclaris Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $42.9 million in 2020, then soared by 42.66% to $61.2 million in 2021, then climbed by 8.91% to $66.7 million in 2022, then rose by 6.23% to $70.8 million in 2023, then climbed by 0.84% to $71.4 million in 2024.